Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Kronos Bio, Inc. (KRON)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 56,030,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Kronos Bio is a late-stage clinical development biopharmaceutical company, with a focus on developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Co.'s primary product candidate, entospletinib, is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor. Co. is also developing lanraplenib, its orally-administered SYK inhibitor. In addition, Co. is developing KB-0742, its internally discovered, oral cyclin dependent kinase 9 inhibitor, for the treatment of MYC-amplified and other transcriptionally addicted solid tumors.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 1,731,056 1,731,056 2,328,185
Total Buy Value $0 $1,470,394 $1,470,394 $3,721,479
Total People Bought 0 1 1 1
Total Buy Transactions 0 3 3 6
Total Shares Sold 31,509 88,959 116,028 169,293
Total Sell Value $33,207 $104,531 $151,964 $246,344
Total People Sold 3 6 7 7
Total Sell Transactions 3 8 11 16
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 97
  Page 1 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Olek Elizabeth A SR VP, CLINICAL SCIENCE   •       –      –    2024-02-21 4 S $1.05 $7,765 D/D (7,368) 193,275     -
   Frisbee Allison SR VP, CORP OPERATIONS & LEGAL   •       –      –    2024-02-21 4 S $1.05 $12,757 D/D (12,105) 204,510     -
   Lin Charles Y SR VP, RESEARCH & DEVELOPMENT   •       –      –    2024-02-21 4 S $1.05 $12,685 D/D (12,036) 234,603     -
   Bischofberger Norbert W PRESIDENT & CEO   •       •      –    2024-02-15 4 A $0.00 $0 D/D 270,339 2,811,004     -
   Dinsmore Christopher Chief Scientific Officer   •       –      –    2024-01-04 4 S $1.18 $8,718 D/D (7,366) 260,969     -
   Dimartino Jorge Chief Medical Officer & VP   •       –      –    2024-01-04 4 S $1.18 $14,214 D/D (12,009) 315,246     -
   Kosacz Barbara COO & General Counsel   •       –      –    2024-01-04 4 S $1.18 $12,636 D/D (10,676) 928,966     -
   Dimartino Jorge Chief Medical Officer & VP   •       –      –    2023-12-12 4 S $1.31 $22,664 D/D (17,367) 327,255     -
   Dinsmore Christopher Chief Scientific Officer   •       –      –    2023-12-12 4 S $1.31 $13,092 D/D (10,032) 268,335     -
   Bischofberger Norbert W President & CEO   •       •      –    2023-11-17 4 B $1.08 $106,162 D/D 97,935 2,540,665 2.81     -
   Bischofberger Norbert W President & CEO   •       •      –    2023-11-16 4 B $1.00 $261,514 D/D 262,433 2,442,730 2.81     -
   Bischofberger Norbert W President & CEO   •       •      –    2023-11-15 4 B $0.80 $1,102,718 D/D 1,370,688 2,180,297 2.81     -
   Dinsmore Christopher Chief Scientific Officer   •       –      –    2023-07-06 4 S $1.75 $11,625 D/D (6,634) 278,367     -
   Dimartino Jorge Chief Medical Officer & VP   •       –      –    2023-07-06 4 S $1.75 $18,956 D/D (10,818) 344,622     -
   Al-Wakeel Yasir B. Chief Financial Officer   •       –      –    2023-07-06 4 S $1.75 $16,852 D/D (9,617) 346,102     -
   Ridloff Elena Director   –       •      –    2023-06-22 4 A $0.00 $0 D/D 11,333 13,963     -
   Dimartino Jorge Chief Medical Officer & VP   •       –      –    2023-02-24 4 S $1.74 $17,621 D/D (10,153) 355,440     -
   Dinsmore Christopher Chief Scientific Officer   •       –      –    2023-02-24 4 S $1.74 $10,918 D/D (6,291) 285,001     -
   Al-Wakeel Yasir B. Chief Financial Officer   •       –      –    2023-02-24 4 S $1.74 $15,665 D/D (9,026) 355,719     -
   Dimartino Jorge Chief Medical Officer & VP   •       –      –    2023-02-15 4 A $0.00 $0 D/D 137,008 365,593     -
   Dinsmore Christopher Chief Scientific Officer   •       –      –    2023-02-15 4 A $0.00 $0 D/D 119,882 291,292     -
   Al-Wakeel Yasir B. Chief Financial Officer   •       –      –    2023-02-15 4 A $0.00 $0 D/D 138,911 364,745     -
   Kosacz Barbara COO & General Counsel   •       –      –    2023-02-15 4 A $0.00 $0 D/D 138,911 939,642     -
   Dinsmore Christopher Chief Scientific Officer   •       –      –    2022-12-12 4 S $1.81 $16,496 D/D (9,138) 162,936     -
   Dimartino Jorge Chief Medical Officer & VP   •       –      –    2022-12-12 4 S $1.81 $33,680 D/D (18,657) 219,478     -
  97 Records found
  1  2  3  4   
  Page 1 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us